var data={"title":"Ofatumumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ofatumumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/400570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ofatumumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ofatumumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22049378\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatitis B virus infection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatitis B virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab, in some cases resulting in fulminant hepatitis, hepatic failure, and death.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Progressive multifocal leukoencephalopathy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Progressive multifocal leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ofatumumab.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9524862\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arzerra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16053099\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Arzerra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9525628\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD20;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609714\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premedicate with acetaminophen, an antihistamine, and a corticosteroid 30 to 120 minutes prior to treatment (see Premedication below).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL), previously untreated:</b> IV: Cycle 1 (cycle is 28 days): 300 mg on day 1, followed by 1,000 mg on day 8; Subsequent cycles: 1,000 mg on day 1 every 28 days; continue for at least 3 cycles until best response or a maximum of 12 cycles (in combination with chlorambucil) (Hillmen 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Premedication:</i> Premedicate with oral acetaminophen (1,000 mg) or equivalent, an oral or IV antihistamine (eg, diphenhydramine 50 mg or cetirizine 10 mg orally or equivalent), and an IV corticosteroid (prednisolone 50 mg or equivalent). Full dose corticosteroid is recommended for the first 2 infusions; in the absence of infusion reaction &ge; grade 3, may reduce or omit corticosteroid dose for subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CLL, relapsed: </b>IV: Cycle 1 (cycle is 28 days): 300 mg on day 1, followed by 1,000 mg on day 8; Subsequent cycles: 1,000 mg on day 1 every 28 days; continue for a maximum of 6 cycles (in combination with fludarabine and cyclophosphamide) (Robak 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Premedication:</i> Premedicate with oral acetaminophen (1,000 mg) or equivalent, an oral or IV antihistamine (eg, diphenhydramine 50 mg or cetirizine 10 mg orally or equivalent), and an IV corticosteroid (prednisolone 50 mg or equivalent). Full dose corticosteroid is recommended for the first 2 infusions; in the absence of infusion reaction &ge; grade 3, may reduce or omit corticosteroid dose for subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CLL, refractory:</b> IV: Initial dose: 300 mg on day 1, followed 1 week later by 2,000 mg once weekly for 7 doses (doses 2 to 8), followed 4 weeks later by 2,000 mg once every 4 weeks for 4 doses (doses 9 to 12; for a total of 12 doses) (Wierda 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Premedication:</i> Premedicate with oral acetaminophen (1,000 mg) or equivalent, an oral or IV antihistamine (eg, diphenhydramine 50 mg or cetirizine 10 mg orally or equivalent), and an IV corticosteroid (prednisolone 100 mg or equivalent). Full dose corticosteroid is recommended for doses 1, 2, and 9; in the absence of infusion reaction &ge; grade 3, may reduce or omit corticosteroid dose for doses 3 to 8; may administer reduced corticosteroid dose (ranging from half to full dose) with doses 10 to 12 if &ge; grade 3 reaction did not occur with dose 9.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CLL, extended treatment:</b> IV: 300 mg on day 1, followed by 1,000 mg on day 8, followed by 1,000 mg 7 weeks later and then every 8 weeks for up to a maximum of 2 years (van Oers 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Premedication:</i> Premedicate with oral acetaminophen (1,000 mg) or equivalent, an oral or IV antihistamine (eg, diphenhydramine 50 mg or cetirizine 10 mg orally or equivalent), and an IV corticosteroid (prednisolone 50 mg or equivalent). Full dose corticosteroid is recommended for the first 2 infusions; in the absence of infusion reaction &ge; grade 3, may reduce or omit corticosteroid dose for subsequent infusions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609715\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609716\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the US manufacturer's labeling; however, there were no clinically relevant pharmacokinetic effects observed in patients with baseline CrCl &ge;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210583\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609717\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Infusion reaction: Interrupt infusion for infusion reaction (any severity). If the reaction resolves or remains at &le; grade 2, resume with the following modifications (based on the grade of the initial reaction):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grade 1 or 2 infusion reaction:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Resume at one-half of the previous rate; may increase (see Administration) based on patient tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grade 3 or 4 infusion reaction: Resume infusion at 12 mL/hour; may increase (see Administration) based on patient tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If reaction severity does not resolve to &le; grade 2 despite management: Consider permanent discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic reaction: Discontinue permanently</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609723\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arzerra: 100 mg/5 mL (5 mL); 1000 mg/50 mL (50 mL) [contains edetate disodium, mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609609\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609718\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV Infusion: <b>Do not administer IV push, IV bolus, or as a subcutaneous injection.</b> Premedicate with acetaminophen, an antihistamine, and a corticosteroid 30 to 120 minutes prior to administration (see Dosing). Infuse in an environment equipped to monitor for and manage infusion reactions. Administer with infusion pump and administration set. Do not exceed infusion rates below. Do not mix with or infuse with other medications. Flush line before and after infusion with NS. Begin infusion within 12 hours of preparation. Interrupt infusion for any severity of infusion reaction; if the reaction resolves or remains at &le; grade 2, may resume infusion (see Dosage Adjustment for Toxicity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Previously untreated chronic lymphocytic leukemia (CLL), relapsed CLL, and extended treatment of CLL:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial 300 mg dose:</i> Initiate infusion at 12 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 25 mL/hour for 30 minutes, if tolerated, increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for 30 minutes, if tolerated increase to 300 mL/hour for 30 minutes, if tolerated, increase to 400 mL/hour for remainder of infusion. Median duration of infusion: 4.8 to 5.2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Subsequent 1,000 mg infusions (if no reaction to previous infusion):</i> Initiate infusion at 25 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for 30 minutes, if tolerated, increase to 400 mL/hour for remainder of infusion. Median duration of infusion: 4.2 to 4.4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Refractory CLL:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Doses 1 and 2:</i> Initiate infusion at 12 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 25 mL/hour for 30 minutes, if tolerated, increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for remainder of infusion. Median duration of infusion: 6.8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Doses 3 to 12:</i> Initiate infusion at 25 mL/hour for 30 minutes, if tolerated (no infusion reaction) increase to 50 mL/hour for 30 minutes, if tolerated, increase to 100 mL/hour for 30 minutes, if tolerated, increase to 200 mL/hour for 30 minutes, if tolerated, increase to 400 mL/hour for remainder of infusion. Median duration of infusion: 4.2 to 4.4 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9525630\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, previously untreated:</b> Treatment of previously untreated chronic lymphocytic leukemia (CLL) (in combination with chlorambucil) when fludarabine-based therapy is considered inappropriate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, relapsed</b>\n      <b>:</b> Treatment of relapsed CLL (in combination with fludarabine and cyclophosphamide).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, refractory:</b> Treatment of CLL refractory to fludarabine and alemtuzumab</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, extended treatment:</b> Extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9525626\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ofatumumab may be confused with obinutuzumab, omalizumab, rituximab</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609618\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (18%), nausea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (24%; &ge;grade 3: &ge;22%; may be prolonged &gt;2 weeks), anemia (16%; grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (65% to 70%; includes bacterial, fungal, or viral), serious infection (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (8% to 23%), cough (19%), upper respiratory tract infection (11% to 19%), dyspnea (14%), bronchitis (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (46%; day 1 reactions: 25% to 44%; subsequent infusions: 2% to 29%), fever (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (9%), hypertension (5%), hypotension (5%), tachycardia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (8%), insomnia (5% to 7%), headache (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (8%), hyperhidrosis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hypogammaglobulinemia (5%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (8%), influenza (6%), herpes zoster (5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (5% to 8%), muscle spasm (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (8%), sinusitis (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Antibody development, hepatitis B (new-onset or reactivation), porphyria cutanea tarda, progressive multifocal leukoencephalopathy, Stevens Johnson syndrome, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609615\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to ofatumumab or any component of the formulation; presence or history of progressive multifocal leukoencephalopathy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609616\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Severe and prolonged (&ge;1 week) cytopenias (neutropenia, thrombocytopenia, and anemia) may occur. Grade 3 or 4 late-onset neutropenia (onset &ge;42 days after last treatment dose) and/or prolonged neutropenia (not resolved 24 to 42 days after last dose) has been reported. Pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred when used in combination with chlorambucil. Monitor blood counts regularly during and after treatment; more frequently if grade 3 or 4 cytopenias develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B virus infection: <b>[US Boxed Warning]: Hepatitis B virus (HBV) reactivation may occur in patients receiving CD20-directed antibody treatment, including ofatumumab; may result in fulminant hepatitis, hepatic failure, and death.</b> Fatal cases of HBV have also occurred in patients not previously infected with HBV. Prior to initiating therapy, obtain hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) measurements in all patients; monitor for clinical and laboratory signs of hepatitis or HBV during and for several months after treatment. HBV reactivation has been reported up to 12 months after therapy discontinuation. Discontinue ofatumumab (and concomitant medications) if viral hepatitis develops and initiate appropriate antiviral therapy. Reactivation has occurred in patients who are HBsAg positive as well as in those who are HBsAg negative but are anti-HBc positive; HBV reactivation has also been observed in patients who had previously resolved HBV infection. Use cautiously in patients who show evidence of prior HBV infection (eg, HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive); consult with appropriate clinicians regarding monitoring and consideration of antiviral therapy before and/or during ofatumumab treatment. The safety of resuming ofatumumab treatment following HBV reactivation is not known; discuss reinitiation of therapy in patients with resolved HBV reactivation with physicians experienced in HBV management.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">- American Society of Clinical Oncology (ASCO) provisional clinical opinion update on hepatitis B virus screening [Hwang 2015]) recommendations: Patients receiving anti-CD20 antibodies are at high risk for hepatitis B virus (HBV) reactivation. Screen for HBV infection infection with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). In addition, patients who have risk factors for HBV infection (eg, birthplace in a country with &ge;2% HBV prevalence, household or sexual contact with HBV infected patients, high-risk behaviors [eg, intravenous drug use], and HIV infection) should also be screened prior to beginning therapy. Initiate prophylactic antiviral therapy (utilizing antivirals with low rates of viral resistance) for HBsAg -positive/anti-HBc -positive patients (without delaying cancer therapy) and continue the antivirals during and for ~6 to 12 months after completing treatment. HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment; antiviral therapy may be initiated prophylactically or begun promptly at the first sign of HBV reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Bacterial, fungal, and new or reactivated viral infections may occur during and/or following therapy; monitor closely for signs/symptoms of infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reaction: May cause serious infusion reactions (some fatal); reactions may include bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia, back pain, abdominal pain, fever, rash, urticaria, angioedema, cytokine release syndrome, and/or anaphylactoid/anaphylactic reactions. Infusion reactions occur more frequently with the first 2 infusions and may occur despite premedication. Premedicate prior to infusion with acetaminophen, an antihistamine, and a corticosteroid. Interrupt infusion for reaction of any severity and institute appropriate treatment; may require subsequent rate modification. Discontinue immediately and permanently if anaphylactic reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy:<b> [US Boxed Warning]: Progressive multifocal leukoencephalopathy (PML) resulting in death may occur with CD20-directed antibody treatment</b>, including ofatumumab. Consider PML in any patient with new onset or worsening neurological symptoms and if PML is suspected, discontinue ofatumumab and evaluate promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has occurred in patients receiving ofatumumab; patients with a high tumor burden and/or high circulating lymphocyte counts (&gt;25,000/mm<sup>3</sup>) are at increased risk for TLS. Administer prophylactic antihyperuricemic therapy and aggressive hydration beginning 12 to 24 hours prior to ofatumumab treatment. Correct electrolyte abnormalities; monitor renal function and hydration status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live vaccines should not be given to patients who have recently received ofatumumab; there is no data concerning secondary transmission. The ability to generate an immune response to any vaccine following treatment is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &ge;65 years experienced a higher incidence of adverse reactions (compared with younger patients).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299781\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9659666\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9523&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609611\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Based on animal data, prolonged depletion of circulating B cells may occur; avoid administering live vaccines to newborns exposed to ofatumumab in utero until B cell recovery occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609614\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ofatumumab is present in human milk. However, human IgG is excreted in breast milk, and therefore, ofatumumab may also be excreted in milk. Available data suggest antibodies present in breast milk do not significantly enter the neonatal and infant circulation. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609721\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (at regular intervals during and after therapy; more frequently if grades 3 or 4 cytopenias develop), renal function, electrolytes</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hepatitis B virus screening recommendations (ASCO provisional clinical opinion update [Hwang 2015]): Screen for hepatitis B virus (HBV) infection with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Signs of active hepatitis B infection (during and for up to 12 months after therapy completion); signs/symptoms of hepatitis; signs or symptoms of infusion reaction; signs of infection; fluid status; signs/symptoms of intestinal obstruction (eg, abdominal pain, repeated vomiting); signs/symptoms of progressive multifocal leukoencephalopathy (focal neurologic deficits, which may present as hemiparesis, visual field deficits, cognitive impairment, aphasia, ataxia, and/or cranial nerve deficits).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609707\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ofatumumab is a monoclonal antibody which binds specifically the extracellular (large and small) loops of the CD20 molecule (which is expressed on normal B lymphocytes and in B-cell CLL) resulting in potent complement-dependent cell lysis and antibody-dependent cell-mediated toxicity in cells that overexpress CD20.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9609709\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 6.1 L (following repeated infusions)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 17.6 days (following repeated infusions)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322753\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (Arzerra Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $682.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/50 mL (50 mL): $6,824.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962018\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arzerra (AE, AT, AU, BB, CH, CZ, DE, DK, EE, ES, FR, GB, HR, HU, IE, IL, IS, JP, KW, LT, LU, MT, NL, NO, PL, PT, QA, RO, SA, SE, SG, SI, UA);</li>\n      <li>Azerra (SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Arzerra (ofatumumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arzerra (ofatumumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coiffier B, Lepretre S, Pedersen LM, et al, &ldquo;Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study,&rdquo; <i>Blood</i>, 2008, 111(3):1094-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/18003886/pubmed\" target=\"_blank\" id=\"18003886\">18003886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i>. 2012;119(16):3698-3704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/22389254/pubmed\" target=\"_blank\" id=\"22389254\">22389254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagenbeek A, Gadeberg O, Johnson P, et al, &ldquo;First Clinical Use of Ofatumumab, a Novel Fully Human Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Follicular Lymphoma: Results of a Phase 1/2 Trial,&rdquo; <i>Blood</i>, 2008, 111(12):5486-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/18390837/pubmed\" target=\"_blank\" id=\"18390837\">18390837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet</i>. 2015;385(9980):1873-1883.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/25882396/pubmed\" target=\"_blank\" id=\"25882396\">25882396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. <i>J Clin Oncol</i>. 2015;33(19):2212-2220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/25964247/pubmed\" target=\"_blank\" id=\"25964247\">25964247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leuk Lymphoma</i>. 2017;58(5):1084-1093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/27731748/pubmed\" target=\"_blank\" id=\"27731748\">27731748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. <i>Lancet Oncol</i>. 2015;16(13):1370-1379. doi: 10.1016/S1470-2045(15)00143-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/26377300/pubmed\" target=\"_blank\" id=\"26377300\">26377300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierda WG, Kipps TJ, D&uuml;rig J, et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i>. 2011;117(24):6450-6458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/20194866/pubmed\" target=\"_blank\" id=\"20194866\">20194866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. <i>J Clin Oncol</i>. 2010;28(10):1749-1755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/20194866/pubmed\" target=\"_blank\" id=\"20194866\">20194866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. <i>Blood</i>. 2011;118(19):5126-5129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ofatumumab-drug-information/abstract-text/21856867/pubmed\" target=\"_blank\" id=\"21856867\">21856867</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9523 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F22049378\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9524862\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16053099\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9525628\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9609714\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9609715\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9609716\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210583\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F9609717\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9609723\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9609609\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9609718\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F9525630\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9525626\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9609618\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9609615\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9609616\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299781\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9659666\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9609611\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9609614\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9609721\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9609707\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F9609709\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322753\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962018\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9523|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ofatumumab-patient-drug-information\" class=\"drug drug_patient\">Ofatumumab: Patient drug information</a></li></ul></div></div>","javascript":null}